Development of specific antisera against 9-desglycinamide-8-arginine vasopressin by site-specific immunization.
Four specific and sensitive antisera against 9-desglycinamide-8-arginine vasopressin (DGAVP) were obtained by means of site-specific immunization in rabbits, using a Keyhole Limpet haemocyanin-DGAVP conjugate synthesized by a specific reaction of a thiol function with a maleimide group. Compared with conventionally raised antisera, the cross-reactivity with endogenous arginine vasopressin (AVP) and vasopressin-derived fragments was substantially lower. Interassay variability was 18.1% at maximum. Possible applicability of the new antisera in pharmacokinetic studies of DGAVP with respect to blood-brain barrier transport was tested by means of a pilot study in the rat.
van Bree
J B
JB
Division of Pharmacology, Leiden University, The Netherlands.
van Nispen
J W
JW
Verhoef
J C
JC
Breimer
D D
DD
D000595:Amino Acid Sequence; D000818:Animals; D000918:Antibody Specificity / Q000276:immunology; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000276:immunology; D003429:Cross Reactions / Q000276:immunology; D005260:Female; D007106:Immune Sera / Q000096:biosynthesis* / Q000276:immunology; D007114:Immunization / Q000379:methods*; D008969:Molecular Sequence Data; D011817:Rabbits; D015203:Reproducibility of Results
D007106:Immune Sera; D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-